Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Huperzine for Cognitive and Functional Impairment in Schizophrenia

This study has been completed.
Yale University
Information provided by (Responsible Party):
Scott Woods, MD, Biomedisyn Corporation Identifier:
First received: August 10, 2009
Last updated: February 28, 2013
Last verified: February 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: December 2012
  Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)